Jace Biomedical

Jace Biomedical is pioneering a targeted approach to treat diseases caused by protein aggregation in the endoplasmic reticulum (ER). Its core technology involves small molecules that inhibit specific ER acetyltransferases (ATases), thereby selectively upregulating ER-specific autophagy (reticulophagy) to degrade toxic protein aggregates without inducing global cellular autophagy. The company is building a pipeline anchored by a lead program for Alzheimer's disease, with potential expansion into other neurodegenerative, metabolic, and rare diseases driven by similar proteotoxic mechanisms. JBI is a private, preclinical-stage company leveraging a novel mechanistic insight to address a significant unmet medical need across multiple indications.

Small molecule platform targeting ER-resident acetyltransferases (ATases) to selectively induce endoplasmic reticulum-specific autophagy (reticulophagy) for clearance of toxic protein aggregates.

Competition includes other companies developing autophagy modulators (e.g., Casma Therapeutics, Caraway Therapeutics), though many aim at global autophagy. In specific indications like Alzheimer's, competition is intense from large pharma and biotechs targeting amyloid, tau, and other pathways. For A1ATD, competitors include protein folding correctors, siRNA therapies, and gene editing approaches, but JBI's mechanism of clearing aggregates via reticulophagy appears distinct.